Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Bloomberg BNA Medical Devices Law & Industry Report, in “Rx, Device Groups Tell FDA to Scrap Latest Off-Label Rule,” by Dana Elfin. (Read the full version – subscription required.)
Following is an excerpt:
The manufacturers’ free speech concerns shouldn’t be downplayed, Bradley Merrill Thompson, a health-care attorney at Epstein Becker & Green PC in Washington, told Bloomberg BNA July 25. Thompson is a Bloomberg BNA advisory board member.
“The question is really whether medical device or pharmaceutical companies should be permitted to share the best information with these physicians to help inform their decision-making, decision-making they are already engaged in,” he said in an email. “It’s by the sharing of such information that our overall knowledge base advances.”
